Abstract Coronavirus disease 2019 (COVID-19) was first detected in December 2019. In
March 2020, the World Health Organization declared COVID-19 a pandemic. People with …

Clinicians and patients around the world have been intrigued by the concept of developing
an oral anticoagulant with a broad therapeutic window and few drug and dietary interactions …

HIV infection has been recognized as a prothrombotic condition and this association has
now been proven by a large number of studies with a reported VTE frequency among HIV …

Inflammation and venous thrombosis are intertwined. Only in the recent 15 years clinical
epidemiological studies have focussed on inflammatory or infectious diseases as risk factors …

Dabigatran etexilate (DE) is a P-glycoprotein (P-gp) probe substrate, and its active
anticoagulant moiety, dabigatran, is a substrate of the multidrug and toxin extrusion protein …

Infection with HIV increases the risk for lung diseases, including noninfectious pulmonary
hypertension (PH). HIV-associated PH (HIV-PH) is an important lung disease in HIV-infected …

The risk of venous thromboembolism (VTE) and of recurrent VTE remain elevated in people
living with HIV compared to controls still with contemporary antiretroviral therapy (ART). The …

Background: Arterial and venous thrombotic events are more prevalent in HIV infected
individuals compared to the general population, even in the era of combination antiretroviral …

Venous thromboembolic disease often arises as a complication of another pathological
condition and/or triggering event. Infectious diseases result from both the direct action of the …

The human immunodeficiency virus (HIV) was unknown until the early 1980's but since then
has infected millions of persons in a worldwide pandemic. The result of HIV infection is …